Discussion paper on pan-tumour biomarker testing to determine eligibility for targeted treatment.
Morona, J, Wyndham, A, Scott, P, Mitchell, A, Merlin, T
Record ID 32018000644
English
Authors' objectives:
To provide guidance on the evidence needed to evaluate immunohistochemistry (IHC) testing for mismatch repair deficiency (dMMR) in colorectal cancer (CRC) and many other types of tumour (pan-tumour or tumour agnostic), in order to access pembrolizumab treatment. Subsequent co-dependent technology submissions seeking subsidy for biomarker testing for treatments that have pan-tumour effects may also be assessed according to this guidance.
Details
Project Status:
Completed
Year Published:
2020
URL for published report:
http://msac.gov.au/internet/msac/publishing.nsf/Content/09DFCADF3138D2B2CA2586E0007D539C/$File/Discussion%20paper%202020-01-13.pdf
English language abstract:
An English language summary is available
Publication Type:
Other
Country:
Australia
MeSH Terms
- Biomarkers, Tumor
- Immunohistochemistry
Keywords
- pan-tumour
- tumour agnostic
- colorectal cancer
- pembrolizumab
Contact
Organisation Name:
Adelaide Health Technology Assessment
Contact Address:
School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617
Contact Name:
ahta@adelaide.edu.au
Contact Email:
ahta@adelaide.edu.au
Copyright:
<p>Adelaide Health Technology Assessment (AHTA) on behalf of NICS</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.